-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
Tender Notice for Pharmacodynamic Study of Recombinant Human Endostatin Injection (M2ES) Combined with Chemotherapy and Single-Drug Long-Term Toxicity Study
Published Time:
2019-03-22 14:38
Tender Announcement
1. Beijing Progen Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “ Tenderer ” ）hereby invites bids from NMPA GLP certified units with relevant business qualifications for conducting pharmacological and toxicological evaluation research of new drugs, for the tenderer's required research projects on the pharmacodynamic study of combined chemotherapy and long-term toxicity study of single-drug polyethylene glycol recombinant human endostatin injection ( M2ES ) Bidding is hereby announced.
2. Experiment Period: Commencing from the date of contract signing 15 months to deliver the report.
3. Location for Delivery of Documents and Materials: Kaituo Road, Shangdi, Haidian District, Beijing 5 ZGC Biomedicine Park B415
4. No Q&A session will be organized for this tender.
5. Tender documents shall be submitted on March 29, 2019 (13:00) on the day of bidding.
6. Tender Document Acquisition, Address and Contact Person for Submission of Tender Documents:
Contact Persons: An Yajun, Zhou Daifu
Contact Number: 136 9922 3097，186 1380 8589
Contact Person E-mail: anyajun@protgen.com ， zhoudaifu@protgen.com
Contact Address: Kaituo Road, Shangdi, Haidian District, Beijing 5 ZGC Biomedicine Park B415
7. Tender documents shall be submitted in one original and two copies (three in total), sealed and stamped as required. Tender documents received after the deadline will be rejected.
Related Recommendations
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC